

## **Product datasheet for TR312842**

## 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436

OriGene Technologies, Inc.

Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **GALT Human shRNA Plasmid Kit (Locus ID 2592)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** GALT Human shRNA Plasmid Kit (Locus ID 2592)

**Locus ID:** 2592

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: GALT - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

2592). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** NM 000155, NM 001258332, NM 147131, NM 147132, NM 000155.1, NM 000155.2,

NM 000155.3, NM 001258332.1, BC015045, BC015045.2, NM 000155.4

UniProt ID: P07902

Summary: Galactose-1-phosphate uridyl transferase (GALT) catalyzes the second step of the Leloir

pathway of galactose metabolism, namely the conversion of UDP-glucose + galactose-1-phosphate to glucose-1-phosphate + UDP-galactose. The absence of this enzyme results in classic galactosemia in humans and can be fatal in the newborn period if lactose is not removed from the diet. The pathophysiology of galactosemia has not been clearly defined. Two transcript variants encoding different isoforms have been found for this gene. [provided

by RefSeq, Apr 2012]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).